Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 05:35 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Phase 2 Study of Atacicept in Subjects With Relapsing Multiple Sclerosis (ATAMS)
NCT00642902 · EMD Serono · PHASE2 · terminated · last registry update 2016-05-24 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Sponsor voluntarily decided to terminate trial due to increased MS disease activity in atacicept arms as compared to placebo during a routine IDMC review.” | – | Registry record, EMD Serono |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against TNFSF13B within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2017-05-23Also stopped (terminated): Anthera Pharmaceuticals, Blisibimod + Placebo (NCT02514967)
- 2017-04-28Results posted on the registry: Human Genome Sciences Inc., a GSK Company, Belimumab (NCT00583362)
- 2017-04-25Results posted on the registry: GlaxoSmithKline, Belimumab + Placebo (NCT01536379)
- 2017-03-22Also stopped (withdrawn): GlaxoSmithKline, Belimumab 10 mg + Placebo (NCT01762852)
- 2017-03-20Also stopped (terminated): EMD Serono, Atacicept 25 mg + Atacicept 75 mg (NCT00853762)
- 2017-02-28Results posted on the registry: University of Pennsylvania, Belimumab (NCT01025193)
- 2016-12-30Results posted on the registry: Merck KGaA, Darmstadt, Germany, Rituximab + Atacicept (NCT00664521)
- 2016-12-02Results posted on the registry: GlaxoSmithKline, Belimumab + Placebo (NCT01345253)
- 2016-07-25Results posted on the registry: Human Genome Sciences Inc., a GSK Company, Belimumab plus Early Vaccination + Belimumab plus Late Vaccination (NCT01597492)
- 2016-05-24Results posted on the registry: EMD Serono, Atacicept 25 mg + Atacicept 75 mg (NCT00853762)
- 2016-04-27Results posted on the registry: GlaxoSmithKline, Belimumab (NCT01480596)
- 2016-03-28Results posted on the registry: Human Genome Sciences Inc., a GSK Company, Belimumab 1 mg/kg + Belimumab 10 mg/kg (NCT00724867)
- 2016-03-23Results posted on the registry: EMD Serono, Atacicept + Mycophenolate mofetil (NCT00573157)
- 2016-03-23Also stopped (terminated): EMD Serono, Atacicept + Mycophenolate mofetil (NCT00573157)
- 2016-03-14Results posted on the registry: EMD Serono, Atacicept 75 mg + Atacicept 150 mg (NCT00624338)
- 2016-02-17Results posted on the registry: EMD Serono, Atacicept + Placebo matched to atacicept (NCT00624468)
- 2016-02-17Also stopped (terminated): EMD Serono, Atacicept + Placebo matched to atacicept (NCT00624468)
- 2016-02-17Results posted on the registry: EMD Serono, Atacicept + Atacicept (NCT00430495)
- 2016-02-17Results posted on the registry: EMD Serono, Placebo matched to atacicept + Atacicept: with loading dose (NCT00595413)
- 2015-08-13Also stopped (withdrawn): Anthera Pharmaceuticals, Blisibimod + Placebo (NCT02074020)
- 2015-08-04Phase 3 first posted: Anthera Pharmaceuticals, Blisibimod + Placebo (NCT02514967)
- 2015-07-30Also stopped (withdrawn): Anthera Pharmaceuticals, Blisibimod + Placebo (NCT02052219)
- 2015-07-30Also stopped (withdrawn): Anthera Pharmaceuticals, Blisibimod + Placebo (NCT01598857)
- 2015-07-30Also stopped (withdrawn): Anthera Pharmaceuticals, Blisibimod (NCT01609452)
- 2015-06-01Results posted on the registry: GlaxoSmithKline, belimumab (NCT01610492)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision